Targeting mTOR in Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia (ALL) is an aggressive hematologic disorder and constitutes approximately 25% of cancer diagnoses among children and teenagers. Pediatric patients have a favourable prognosis, with 5-years overall survival rates near 90%, while adult ALL still correlates with poorer surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Simioni, Carolina, Martelli, Alberto M., Zauli, Giorgio, Melloni, Elisabetta, Neri, Luca M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406494/
https://www.ncbi.nlm.nih.gov/pubmed/30795552
http://dx.doi.org/10.3390/cells8020190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406494/
https://www.ncbi.nlm.nih.gov/pubmed/30795552
http://dx.doi.org/10.3390/cells8020190

Ejemplares similares